Protease inhibitors
CA 2406829 A1 · Owner: Smithkline Beecham Corporation · Inventors: Marquis, Robert W. Jr.; Cummings, Maxwell D.; Veber, Daniel F.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin S in the treatment of diseases in which cathepsin S is implicated, especially treatment or prevention of autoimmune disease; treatment or prevention of a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition, for therapy, of a class II MHC-restricted immune response, inhibition of an asthmatic response inhibition of an allergic , response, inhibition of immune response against a transplanted organ or tissue, or inhibition of elastase activity in atheroma and novel compounds , for use therewith.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 17, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 17, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 17, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.